18:25 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Synchronous signaling

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...
23:12 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Patient sample and mouse studies suggest inhibiting the interactions between CD69 and its ligands MYL9 , MYL12A and MYL12B could help treat allergic asthma. In nasal polyp samples from patients with the allergic...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Amarantus BioScience, Avant Diagnostics deal

Avant acquired Amarantus BioScience’s Amarantus Diagnostics Inc. subsidiary for 80 million shares of Avant stock valued at $25.6 million based on Avant’s close of $0.32 on May 11, the day before the deal closed. Amarantus...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Updated Phase IIb data

Updated data from a subgroup of 196 NSCLC patients with non-squamous tumors in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy significantly...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

LymPro Test: Pilot trial data

Preliminary data from 125 blood samples from 59 AD patients and 66 controls in the U.S. pilot LP-002 trial showed that the LymPro test met the primary endpoint of replicating data published in peer-reviewed publications....
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Amarantus BioScience sales and marketing update

Amarantus launched blood diagnostic LymPro to detect Alzheimer’s disease (AD). The diagnostic is only available for pharmaceutical companies, but Amarantus plans to launch a version of the test in the U.S. under CLIA designation for...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

LymPro Test: Pilot trial completed enrollment

Amarantus completed enrollment of 72 patients in the U.S. pilot LP-002 trial of its LymPro Test. Amarantus is also evaluating LymPro as a test for traumatic brain injury (TBI) and chronic traumatic encephalopathy. In April,...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

University of Leipzig, Amarantus BioScience deal

The University of Leipzig granted Amarantus an exclusive option to license IP related to methods of modulating the expression of cyclin dependent kinase inhibitor 2A ( CDKN2A ; INK4a ; ARF; p16INK4a ) in the...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Updated Phase IIb data

Updated data from 217 patients with MUC1-positive stage IV NSCLC in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy met the primary...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Phase IIb data

Top-line data from 210 patients with MUC1-positive stage IV NSCLC in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy missed the primary...